Abstract Library

#4089 Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,

Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,

#4017 Serum 5-hydroxyindoleacetic acid is equivalent to 24-hour urinary 5-hydroxyindoleacetic acid for the diagnosis of carcinoid syndrome

Introduction: Neuroendocrine tumors (NET) are characterized by their ability to secrete amines and peptides. Overproduction of serotonin results in the carcinoid syndrome (CS), present in approximately 20% of all NET patients. Measuring the main metabolite of serotonin, 5-hydroxyindoleacetic acid (5-HIAA), in 24-hour urine is frequently used for the diagnosis and follow-up of CS patients. However, these measurements are prone to sampling error and may be troublesome for patients. Serum 5-HIAA measurements might be a more reliable and convenient alternative in the diagnosis of CS.

Conference:

Presenting Author:

Authors: Kerolles M, Mulders M, Mirzaian M, van den Berg S, Feelders R,

Keywords: 5-hiaa, carcinoid syndrome, neuroendocrine tumor, biomarker,

#3863 Survival and prognostic factors in appendiceal neuroendocrine tumors (ANET) and goblet cell carcinoma (aGCC)

Introduction: Appendiceal goblet cell carcinomas (aGCC) present with overlapping features of appendiceal neuroendocrine neoplasms (ANET) and adenocarcinomas. A previous study found that ANET with peritoneal metastases have a 5-year survival rate of 7%. Recent studies show that ANET rarely metastasizes, contrary to aGCC. The latest WHO classification excluded aGCC from the group of NETs and classified it as appendiceal adenocarcinomas.

Conference:

Presenting Author: Dijke K

Authors: Dijke K, Levy S, van den Berg J, Tesselaar M,

Keywords: Goblet cell carcinoma, Appendiceal neuroendocrine tumor, Survival,

#3559 Novel patient-derived tumor organoid models reveal growth-factor dependencies in neuroendocrine tumors and serve as a platform for neuroendocrine cancer research

Introduction: Neuroendocrine neoplasms (NENs) comprise neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). While NETs are well-differentiated and progress slowly, NECs are poorly differentiated and have a poor prognosis. Irrespective of subtype, treatment options for patients with unresectable, relapsed, or metastasized NENs are limited, in part due to lack of accurate models to study these diseases.

Conference:

Presenting Author: Dayton T

Authors: Dayton T, Alcala N, Moonen L, van den Berg J, Buikhuisen W,

Keywords: patient derived tumor organoids, pulmonary NET, LCNEC, growth-factor dependency,

#3049 Organoid Models of Neuroendocrine Cell Growth and Tumorigenesis

Introduction: A paucity of in vitro and in vivo models has limited the study of Neuroendocrine neoplasms (NENs). Moreover, little is known about normal neuroendocrine (NE) cells and how they contribute to NEN formation.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dayton T, Den Hartigh L, Levy S, van den Berg J, Kok N,

Keywords: Organoids, NENs, pulmonary neuroendocrine cells,